The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease

被引:2
|
作者
Gajos, Andrea [1 ]
Tapper, Elliot B. [1 ,2 ]
机构
[1] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA
[2] VA Ann Arbor Healthcare Syst, Gastroenterol Sect, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
cirrhosis; obesity; liver transplant; patient centered care; RANDOMIZED CONTROLLED-TRIAL; WEIGHT-LOSS; CIRRHOSIS; EPIDEMIOLOGY; EFFICACY; QUALITY; ADULTS;
D O I
10.1016/j.clinthera.2020.12.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States. NAFLD presents unique challenges to conventional health care delivery. Patients require accurate, efficient risk stratification to both individualize clinical management plans and optimize subspecialty resource allocation The hepatology workforce is grossly outmatched by the demand for NAFLD referrals, however. Advanced practice providers (APPs) may be best suited to meeting the challenges of NAFLD care. This article reviews the nature and scope of APP practice, the specific needs posed by NAFLD, and the evidence supporting the comparative advantages of APPs in optimizing the outcomes of patients with NAFLD. Our goal is to show how APPs are uniquely suited to addressing the needs of patients with NAFLD who are seen in hepatology practice, with an emphasis on training philosophy and behavioral intervention. (C) 2020 Elsevier Inc.
引用
收藏
页码:518 / 523
页数:6
相关论文
共 50 条
  • [31] The role of the gut microbiota in nonalcoholic fatty liver disease
    Ahmed Abu-Shanab
    Eamonn M. M. Quigley
    Nature Reviews Gastroenterology & Hepatology, 2010, 7 : 691 - 701
  • [32] Role of cenicriviroc in the management of nonalcoholic fatty liver disease
    Neokosmidis, Georgios
    Tziomalos, Konstantinos
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (48) : 5415 - 5417
  • [33] Role of vitamin E in nonalcoholic fatty liver disease
    Nagashimada, Mayumi
    Ota, Tsuguhito
    IUBMB LIFE, 2019, 71 (04) : 516 - 522
  • [34] Treatment of nonalcoholic fatty liver disease: role of AMPK
    Smith, Brennan K.
    Marcinko, Katarina
    Desjardins, Eric M.
    Lally, James S.
    Ford, Rebecca J.
    Steinberg, Gregory R.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2016, 311 (04): : E730 - E740
  • [35] Role of histone deacetylase on nonalcoholic fatty liver disease
    Fu, Shifeng
    Yu, Meihong
    Tan, Yuyong
    Liu, Deliang
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (04) : 353 - 361
  • [36] The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease
    Doumas, Michael
    Imprialos, Konstantinos
    Dimakopoulou, Aikaterini
    Stavropoulos, Konstantinos
    Binas, Athanasios
    Athyros, Vasilios G.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (38) : 4587 - 4592
  • [37] The role of the gut microbiota in nonalcoholic fatty liver disease
    Abu-Shanab, Ahmed
    Quigley, Eamonn M. M.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (12) : 691 - 701
  • [38] Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease
    Aqel, Bashar
    DiBaise, John K.
    NUTRITION IN CLINICAL PRACTICE, 2015, 30 (06) : 780 - 786
  • [39] Nonalcoholic fatty liver disease: Pathogenesis and the role of antioxidants
    Mehta, K
    Van Thiel, DH
    Shah, N
    Mobarhan, S
    NUTRITION REVIEWS, 2002, 60 (09) : 289 - 293
  • [40] Role of nonalcoholic fatty liver disease in hepatocellular carcinoma
    Chavez-Tapia, Norberto C.
    Mendez-Sanchez, Nahum
    Uribe, Misael
    ANNALS OF HEPATOLOGY, 2009, 8 : S34 - S39